ClinicalTrials.gg
Not yet recruitingNCT05043181ENDFHUpdated Sep 14, 2021

Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH

A Phase 1 interventional study of Low Density Lipoprotein Receptor mRNA Exosomes in Familial Hypercholesterolemia, sponsored by Tang-Du Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Tang-Du Hospital · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.

Planned enrollment
17th of 22
30 · median 142
Started
2021
with 3 others
Phase 1
5 of 24
4 open now
Primary completion
2026-12
later than 4 of 12 live
Registered
7th of 24
by date

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 17th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 1, reaches primary completion later than 4 of the 12 other live ones, and was the 7th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

mRNA therapy is a highly promising gene therapeutic strategy in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). Exosomes is safe and efficient carriers for mRNA drug delivery, due to their biocompatibility, bioavailability. This first-in-human study is aimed to evaluate the safety and preliminary effectiveness of Exosome-based ldlr mRNA nanoplatform for gene therapy in HoFH.

Read the detailed description

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease characterized by severely elevated plasma low-density lipoprotein (LDL) cholesterol (LDL-C) and premature coronary heart disease. Most of FH patients (about 95% of cases) are attributed to functional loss mutation of the LDL receptor (LDLR) gene. The prevalence of the heterozygous mutations in LDLR has been estimated at 1 in 200 to 1 in 500 in the population, and the homozygous form in 1 in 100000 individuals. As a key lipoprotein receptor on the surface of hepatocyte, the LDLR is critical for liver clearing LDL-C from the circulation. By endocytosis and further processing of the LDL-C, LDLR is responsible for removing most excess LDL-C from the serum, and there are no substitutes in vivo. These heterozygotes (HeFH) typically have twice the normal plasma LDL levels and cardiovascular diseases at an earlier age. Homozygous individuals (HoFH) face much higher LDL-C levels and often die before the age of 20 years if untreated. Although existing therapeutics, such as statins, ezetimibe and PCSK9 inhibitors, have some beneficial effects on HeFH, few drugs have therapeutic effects on HoFH even at high-doses. Lipid apheresis and liver transplantation are the current clinical managements to reduce the LDL-C level, while gene therapy holds the promise.

Exosomes are small intracellular vesicles ranging in 30-150 nm size and have an important role in cell-cell communication. Many studies show that exosome can efficiently deliver cargos, such as mRNA, miRNA and even plasmid DNA, to target cells, emerging as a promising therapeutic carrier for gene therapy. Compared with virus, exosomes, as "natural nanoparticles", are easy to handle, non-cytotoxic and non-immunogenic. It is thus promising to develop exosome-based LDLR-gene delivery strategy and explore the therapeutic effects on HoFH.

In this study, an Ldlr-expressing virus vector will be constructed to generate Ldlr mRNA-enriched exosomes. To meet the standards of clinical trials, we will use the GMP-grade compliant normal donor bone marrow-derived MSCs to produce exosomes. Exosomes will be enriched by filtration and ultracentrifugation, and then normalized by Nanosight, Electron microscopy and key exosomes biomarkers. In order to ensure the safety of patients, we plan to inject exosomes through abdominal puncture under ultrasound guidance, and purchase medical insurance for patients. This first-in-human study is aimed to evaluate the safety of this exosome product for gene therapy and preliminary evidence of efficacy using plasma LDL-C levels as a surrogate biomarker. The study is promising to provide a new therapeutic approach for the treatment of Homozygous Familial Hypercholesterolemia patients.

03

Conditions studied

  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-45, no gender limitation;
  2. Patients with homozygous familial hypercholesterolemia diagnosed by genetic testing.
  3. Understand the study and be willing to participate in the study with the signed

Exclusion criteria

Exclusion Criteria:

  1. those who have severe comorbidities, including any of the following: A) unstable angina pectoris and/or congestive heart failure requiring hospitalization; B) myocardial infarction or cerebrovascular accident within the last 6 months; C) worsens or requires hospitalization; D) serious diseases of vascular, nervous system, blood, gastrointestinal and endocrine systems or metabolic disorders; E) /immune deficiency diseases such as rheumatoid arthritis, acquired immune deficiency syndrome, and so on; F) malignant tumor or other chronic infection.
  2. those who previously received targeted drug therapy, cell therapy, gene therapy or others immunotherapy;
  3. those who had organ transplants in the past;
  4. any of the following abnormalities are found in the laboratory examination: A) blood routine examination: (ANC) \< 1.5×109/L, or (PLT) \< 50×109/L, or (HGB) \< 80 g/dL; B) coagulation function: (PT), or activated partial thrombin time (APTT), or INR > 1.5×; C) liver function: total (TBIL) > 2×ULN (upper limit of normal value), or alanine transferase (), aspartate transferase (AST), alkaline phosphatase (ALP) > 5×ULN; D) renal function: serum creatinine (Cr) ≥1.5×ULN, or (GFR) \< 60 mL/min·1.73m2; E) cardiac ultrasound: (LVEF) \< 50%.
  5. those who are known or expected to have an allergic reaction to or have a history of allergic reaction to any of the ingredients treated by this test;
  6. those who have a history of contrast agent allergic;
  7. those who have a clear history of mental disorders in the past;
  8. those who have a history of drug abuse or drug use;
  9. Pregnant or lactating women;
  10. Women of childbearing age and fertile men cannot take effective and adequate measures (such as intrauterine device (IUD), condom, spermicidal gel plus condom, uterine cap, etc.) during the period of receiving the study drug and 3 months after the end of the study;
  11. those who participated in the clinical study of other drugs within 3 months before joining the group;
  12. Subjects that are not suitable to participate in this study for other reasons judged by the investigators.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Homozygous Familial Hypercholesterolemia

    Biological: Low Density Lipoprotein Receptor mRNA Exosomes

Interventions

  • BiologicalLow Density Lipoprotein Receptor mRNA Exosomes

    The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase:For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d. Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase.

06

What researchers measure

Primary outcomes

  1. Changes of Total Cholesterol

    mmol/L

    Time frame: Changes from Baseline Total Cholesterol at Day 19

  2. Changes of Low-Density Lipoprotein Cholesterol

    mmol/L

    Time frame: Changes from Baseline Low-Density Lipoprotein Cholesterol at Day 19

  3. Changes of High-Density Lipoprotein Cholesterol

    mmol/L

    Time frame: Changes from Baseline High-Density Lipoprotein Cholesterol at Day 19

  4. Changes of Triglyceride

    mmol/L

    Time frame: Changes from Baseline Triglyceride at Day 19

Secondary outcomes

  1. Changes of Degree of Coronary Stenosis

    % determined by coronary CT

    Time frame: Changes from Baseline Degree of Coronary Stenosis at Day 28

  2. Changes of Volume of Carotid Artery Plaques

    cm3 determined by ultrasound

    Time frame: Changes from Baseline Volume of Carotid Artery Plaques at Day 28

  3. Changes of Stability of Carotid Artery Plaques

    Grade I, II, III determined by ultrasound

    Time frame: Changes from Baseline Stability of Carotid Artery Plaques at Day 28

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2021; primary completion for Dec 2026, 60 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2021
First posted
Sep 14, 2021
StartEst.
Dec 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05043181
Lead sponsor
Tang-Du Hospital
Responsible party
Lijun Yuan, MD, PhD (Director of the department of ultrasound diagnostics, Tang-Du Hospital) — Principal investigator
First posted
Sep 14, 2021
Start date
Dec 2021 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 14, 2021

Study contacts

Zhelong Li
Contact
lzlfmmu@foxmail.com
13319189556
Changyang Xing
Contact
xingcy712@163.com
13571864787
Lijun Yuan
principal investigator · Tangdu Hospital, Air Force Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion